1. Home
  2. TCBP vs ARTL Comparison

TCBP vs ARTL Comparison

Compare TCBP & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TCBP
  • ARTL
  • Stock Information
  • Founded
  • TCBP 2013
  • ARTL 2011
  • Country
  • TCBP United Kingdom
  • ARTL United States
  • Employees
  • TCBP N/A
  • ARTL N/A
  • Industry
  • TCBP Biotechnology: Biological Products (No Diagnostic Substances)
  • ARTL Biotechnology: Pharmaceutical Preparations
  • Sector
  • TCBP Health Care
  • ARTL Health Care
  • Exchange
  • TCBP Nasdaq
  • ARTL Nasdaq
  • Market Cap
  • TCBP 831.0K
  • ARTL 3.6M
  • IPO Year
  • TCBP 2022
  • ARTL N/A
  • Fundamental
  • Price
  • TCBP $1.69
  • ARTL $0.95
  • Analyst Decision
  • TCBP Strong Buy
  • ARTL Strong Buy
  • Analyst Count
  • TCBP 1
  • ARTL 2
  • Target Price
  • TCBP $48.00
  • ARTL $5.50
  • AVG Volume (30 Days)
  • TCBP 632.6K
  • ARTL 27.2K
  • Earning Date
  • TCBP 11-25-2024
  • ARTL 03-03-2025
  • Dividend Yield
  • TCBP N/A
  • ARTL N/A
  • EPS Growth
  • TCBP N/A
  • ARTL N/A
  • EPS
  • TCBP N/A
  • ARTL N/A
  • Revenue
  • TCBP N/A
  • ARTL N/A
  • Revenue This Year
  • TCBP N/A
  • ARTL N/A
  • Revenue Next Year
  • TCBP N/A
  • ARTL N/A
  • P/E Ratio
  • TCBP N/A
  • ARTL N/A
  • Revenue Growth
  • TCBP N/A
  • ARTL N/A
  • 52 Week Low
  • TCBP $1.43
  • ARTL $0.91
  • 52 Week High
  • TCBP $523.20
  • ARTL $1.70
  • Technical
  • Relative Strength Index (RSI)
  • TCBP 28.01
  • ARTL 30.40
  • Support Level
  • TCBP $1.43
  • ARTL $0.94
  • Resistance Level
  • TCBP $2.19
  • ARTL $1.01
  • Average True Range (ATR)
  • TCBP 0.28
  • ARTL 0.05
  • MACD
  • TCBP 0.19
  • ARTL -0.01
  • Stochastic Oscillator
  • TCBP 20.57
  • ARTL 4.78

About TCBP TC BioPharm (Holdings) plc

TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled the company to develop a range of clinical-stage cell therapies designed to combat cancer and viral infection.

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors and neurotransmitters that form a biochemical communication network in body. It is focused on discovering, licensing, developing, and commercializing treatments that control endocannabinoid systems. The company pursues technologies and programs that offer proprietary approaches to cannabinoid-based therapies, also those derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare and orphan disease.

Share on Social Networks: